Prognostic value of hematologic parameters in advanced non-small cell lung cancer patients receiving anti-PD-1 inhibitors

BackgroundThe association between hematologic parameters and anti-programmed death-1 (PD-1) inhibitors was generally examined without considering therapy lines and medicine types. The study was aimed to identify potential hematologic biomarkers associated with clinical outcome in patients with non-small cell lung cancer (NSCLC) treated with first-line pembrolizumab and subsequent-line nivolumab. Materials and methods161 NSCLC patients were categorized into first-line pembrolizumab group (pembrolizumab group) and subsequent-line nivolumab group (nivolumab group). Univariate and multivariate Cox regression analyses were used to evaluate the prognostic value of hematologic parameters for clinical outcomes. ResultsThe median progression-free survival (mPFS) was 9.6 months in the pembrolizumab group and 4.1 months in the nivolumab group (HR =1.61; P = 0.012); the median overall survival (mOS) was not reached in the pembrolizumab group and 17.7 months in the nivolumab group (HR =1.37; P = 0.23). Of the 79 patients in the pembrolizumab group, baseline PD-L1 tumor proportion score (TPS)>= 1% was an independent factor of longer PFS and OS. Age >= 60 years, absolute platelet count (APC)>= 220x10(9)/L and platelet-to-lymphocyte ratio (PLR)>= 120 were associated with inferior PFS. Of the 82 patients in the nivolumab group, absolute neutrophil count (ANC)>= 3x10(9)/L was associated with longer PFS, while LDH (lactate dehydrogenase)>= 160 U/L was associated with inferior PFS and derived neutrophil-to-lymphocyte ratio (dNLR)>= 1.2 was associated with longer OS. ConclusionOur study identified multiple clinically accessible prognostic biomarkers in the peripheral blood in both the pembrolizumab and nivolumab subgroups.